Natalie Trevaskis
Natalie Trevaskis
Verified email at
Cited by
Cited by
Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
CJH Porter, NL Trevaskis, WN Charman
Nature reviews Drug discovery 6 (3), 231-248, 2007
Strategies to address low drug solubility in discovery and development
HD Williams, NL Trevaskis, SA Charman, RM Shanker, WN Charman, ...
Pharmacological reviews 65 (1), 315-499, 2013
Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update
NL Trevaskis, WN Charman, CJH Porter
Advanced drug delivery reviews 60 (6), 702-716, 2008
From sewer to saviour—targeting the lymphatic system to promote drug exposure and activity
NL Trevaskis, LM Kaminskas, CJH Porter
Nature Reviews Drug Discovery 14 (11), 781-803, 2015
50 years of oral lipid-based formulations: provenance, progress and future perspectives
OM Feeney, MF Crum, CL McEvoy, NL Trevaskis, HD Williams, ...
Advanced drug delivery reviews 101, 167-194, 2016
Lipid-based formulations and drug supersaturation: harnessing the unique benefits of the lipid digestion/absorption pathway
HD Williams, NL Trevaskis, YY Yeap, MU Anby, CW Pouton, CJH Porter
Pharmaceutical research 30 (12), 2976-2992, 2013
Intestinal bile secretion promotes drug absorption from lipid colloidal phases via induction of supersaturation
YY Yeap, NL Trevaskis, T Quach, P Tso, WN Charman, CJH Porter
Molecular pharmaceutics 10 (5), 1874-1889, 2013
Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies
S Han, T Quach, L Hu, A Wahab, WN Charman, VJ Stella, NL Trevaskis, ...
Journal of Controlled Release 177, 1-10, 2014
The lymph lipid precursor pool is a key determinant of intestinal lymphatic drug transport
NL Trevaskis, CJH Porter, WN Charman
Journal of Pharmacology and Experimental Therapeutics 316 (2), 881-891, 2006
Targeted drug delivery to lymphocytes: a route to site-specific immunomodulation?
NL Trevaskis, WN Charman, CJH Porter
Molecular pharmaceutics 7 (6), 2297-2309, 2010
Lipid absorption triggers drug supersaturation at the intestinal unstirred water layer and promotes drug absorption from mixed micelles
YY Yeap, NL Trevaskis, CJH Porter
Pharmaceutical research 30 (12), 3045-3058, 2013
The mechanisms of pharmacokinetic food-drug interactions–A perspective from the UNGAP group
M Koziolek, S Alcaro, P Augustijns, AW Basit, M Grimm, B Hens, CL Hoad, ...
European Journal of Pharmaceutical Sciences 134, 31-59, 2019
Intestinal lymphatic transport enhances the post-prandial oral bioavailability of a novel cannabinoid receptor agonist via avoidance of first-pass metabolism
NL Trevaskis, DM Shackleford, WN Charman, GA Edwards, A Gardin, ...
Pharmaceutical research 26 (6), 1486, 2009
A new in vitro lipid digestion–in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations
MF Crum, NL Trevaskis, HD Williams, CW Pouton, CJH Porter
Pharmaceutical research 33 (4), 970-982, 2016
Bile increases intestinal lymphatic drug transport in the fasted rat
NL Trevaskis, CJH Porter, WN Charman
Pharmaceutical research 22 (11), 1863-1870, 2005
An examination of the interplay between enterocyte-based metabolism and lymphatic drug transport in the rat
NL Trevaskis, CJH Porter, WN Charman
Drug metabolism and disposition 34 (5), 729-733, 2006
Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumor-burdened lymph nodes after intravenous and subcutaneous …
LM Kaminskas, VM McLeod, DB Ascher, GM Ryan, S Jones, JM Haynes, ...
Molecular pharmaceutics 12 (2), 432-443, 2015
The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524, 515 and CP532, 623)
NL Trevaskis, CL McEvoy, MP McIntosh, GA Edwards, RM Shanker, ...
Pharmaceutical research 27 (5), 878-893, 2010
The potential for drug supersaturation during intestinal processing of lipid-based formulations may be enhanced for basic drugs
YY Yeap, NL Trevaskis, CJH Porter
Molecular pharmaceutics 10 (7), 2601-2615, 2013
The mechanism of lymphatic access of two cholesteryl ester transfer protein inhibitors (CP524, 515 and CP532, 623) and evaluation of their impact on lymph lipoprotein profiles
NL Trevaskis, RM Shanker, WN Charman, CJH Porter
Pharmaceutical research 27 (9), 1949-1964, 2010
The system can't perform the operation now. Try again later.
Articles 1–20